

Raf Kinases

[View the current Raf Kinases InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Raf_Kinases.html)

(http://www.bioportfolio.com/indepth/Raf_Kinases.html)



Recent Publications on Raf Kinases:

- [RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.](#)
More than half of all colorectal carcinomas are known to exhibit an...27th September, 2008
Department of Cancer Prevention, Institute for Cancer Research, Norwegian- Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686.
- [Sorafenib in lung cancer: clinical developments and future directions.](#)
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related...23rd September, 2008
Department of Thoracic/Head and Neck Oncology, University of Texas, MD,- J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S124-7. ([DOI Direct Link](#))
- [Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.](#)
In advanced metastatic melanoma (AJCC stage IV), the prognosis is still...16th September, 2008
Department of Dermatology, University Hospital of Schleswig-Holstein,- Onkologie. 2008 Jul;31(7):398-403. Epub 2008 Jun 23. ([DOI Direct Link](#))
- [Characterization of S338 phosphorylation for Raf-1 activation.](#)
Raf kinases are essential for regulating cell proliferation, survival and...9th September, 2008
Boston University School of Medicine, Boston, MA 02118.- J Biol Chem. 2008 Sep 5. ([DOI Direct Link](#))
- [BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.](#)
AZD6244 (ARRY 142886) is a potent and selective mitogen-activated protein...9th September, 2008
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.- Cancer Res. 2008 Aug 1;68(15):6145-53. ([DOI Direct Link](#))
- [Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.](#)
Increased Akt phosphorylation was reported in cancer cell lines and tumor...9th September, 2008
Department of Pharmacy Practice and Pharmaceutical Sciences, University of- Anticancer Drugs. 2008 Aug;19(7):681-8. ([DOI Direct Link](#))
- [Raf protects against colitis by promoting mouse colon epithelial cell survival through NF-kappaB.](#)
BACKGROUND & AIMS: Raf-1 kinase is a key regulator of a number of cellular...3rd September, 2008
Department of Cell and Developmental Biology, Vanderbilt University,- Gastroenterology. 2008 Aug;135(2):539-51. Epub 2008 Apr 30. ([DOI Direct Link](#))
- [Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.](#)
Mutations occur in some cancer cells and result in elevated expression or...30th August, 2008
Brody School of Medicine at East Carolina University, Department of- Curr Opin Investig Drugs. 2008 Jun;9(6):614-30.

- [Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.](#)
*PURPOSE: Sorafenib inhibits Raf kinase and vascular endothelial growth...*15th August, 2008
 Medical Oncology Branch, Biostatistics and Data Management Section, and- J Clin Oncol. 2008 Aug 1;26(22):3709-14. ([DOI Direct Link](#))
- [Sorafenib \(BAY 43-9006\): review of clinical development.](#)
*Sorafenib (BAY 43-9006) is a novel oral bis-aryl urea compound originally...*13th August, 2008
 Department of Medical Oncology and Hematology, Princess Margaret Hospital- Curr Clin Pharmacol. 2006 Sep;1(3):223-8.
- [Positive Regulation of A-RAF by Phosphorylation of Isoform-specific Hinge Segment and Identification of Novel Phosphorylation Sites.](#)
*In mammals the RAF family of serine/threonine kinases consists of three...*30th July, 2008
 Institute for Medical Radiation and Cell Research, Institute of- J Biol Chem. 2008 Oct 3;283(40):27239-27254. Epub 2008 Jul 28. ([DOI Direct Link](#))
- [Sorafenib in liver cancer--just the beginning.](#)
*To study spatiotemporal regulation of the mitogen-activated protein kinase...*30th July, 2008
 - N Engl J Med. 2008 Jul 24;359(4):420-2. ([DOI Direct Link](#))
- [Sorafenib in advanced hepatocellular carcinoma.](#)
*BACKGROUND: No effective systemic therapy exists for patients with...*30th July, 2008
 Barcelona Clinic Liver Cancer Group, Institut d'Investigacions Biomediques- N Engl J Med. 2008 Jul 24;359(4):378-90. ([DOI Direct Link](#))
- [RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.](#)
*Raf kinase trapping to Golgi (RKTG) is a newly characterized negative...*30th July, 2008
 Key Laboratory of Nutrition and Metabolism, Institute for Nutritional- Carcinogenesis. 2008 Jun;29(6):1157-63. Epub 2008 May 29. ([DOI Direct Link](#))
- [Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis.](#)
*To study spatiotemporal regulation of the mitogen-activated protein kinase...*29th July, 2008
 Department of Pharmacology, University of Colorado at Denver and Health- Traffic. 2008 Sep;9(10):1776-90. Epub 2008 Jul 24. ([DOI Direct Link](#))

Raf Kinases Clinical Trials:



- [An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma](#)
Cancer; Carcinoma, Renal Cell

Raf Kinases Patents:



- 6670348- [Methods and compositions for destruction of selected proteins](#)
- 7001905- [Substituted diarylamines as MEK inhibitors](#)
- 7019033- [2-\(4-bromo or 4-iodo phenylamino\) benzoic acid derivatives](#)
- 7026336- [Compounds](#)
- 7030119- [Method for treating chronic pain using MEK inhibitors](#)
- 7041453- [Molecular constructs and methods of use for detection of biochemical reactions](#)
- 7067532- [Substituted quinolines as antitumor agents](#)
- 7071216- [Substituted benz-azoles and methods of their use as inhibitors of Raf kinase](#)
- 7078438- [N-\(4 substituted phenyl\)-anthranilic acid hydroxamate esters](#)
- 7141576- [Cancer treatment method](#)
- 7160915- [N-methyl-substituted benzamidazoles](#)
- 6998391- [Method for treating diseases associated with abnormal kinase activity](#)
- 6987119- [Imidazol-2-carboxamide derivatives as raf kinase inhibitors](#)
- 6960614- [Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids](#)
- 6723830- [Short peptides which selectively modulate the activity of protein kinases](#)
- 6750217- [Benzenesulfonamide derivatives and their use as MEK inhibitors](#)
- 6770778- [N-\(4-substituted phenyl\)-anthranilic acid hydroxamate esters](#)
- 6803360- [Compositions and methods for reducing radiation and drug resistance in cells](#)
- 6809106- [Quinoline derivatives as inhibitors of MEK enzymes](#)
- 6821963- [4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors](#)
- 6833436- [Short peptides which selectively modulate the activity of serine/threonine kinases](#)
- 6835749- [Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors](#)
- 6891066- [N-\(4-substituted phenyl\)-anthranilic acid hydroxamate esters](#)
- 6916846- [Coumermycin analogs as chemical dimerizers of chimeric proteins](#)
- 7169816- [4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors](#)
- 7173135- [Substituted 3-cyanoquinolines as MEK inhibitors](#)
- 7351834- [.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors](#)
- 7354945- [2-oxadiazolechromone derivatives](#)
- 7368542- [Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions](#)
- 7371763- [Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas](#)
- 7375105- [Pyridine substituted furan derivatives as Raf kinase inhibitors](#)
- 7378233- [BRAF mutation T1796A in thyroid cancers](#)
- 7378421- [Chromenone derivatives](#)
- 7402583- [Substituted quinolines as antitumor agents](#)
- 7411001- [Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids](#)
- 7423150- [Substituted benzazoles and methods of their use as inhibitors of Raf kinase](#)
- 7329670- [Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas](#)
- 7320864- [Methods of using molecular constructs for detection of biochemical reactions](#)
- 7307100- [2-Benzoylchromone derivatives](#)
- 7173136- [3-Cyano-quinoline derivatives](#)
- 7199137- [Imidazole derivatives as Raf kinase inhibitors](#)
- 7235576- [Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors](#)
- 7235658- [Imidazol derivatives as Raf kinase inhibitors](#)
- 7250434- [CCK-1 receptor modulators](#)
- 7253184- [4-Substituted quinolines as antitumor agents](#)
- 7273877- [5-substituted-4-\[\(substituted phenyl\) amino\]-2-pyridone derivatives](#)
- 7282500- [Imidazole-2-carboxamide derivatives as Raf kinase inhibitors](#)
- 7297693- [Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors](#)
- 7297694- [Pyridylfurans and pyrroles as Raf kinase inhibitors](#)
- 7429667- [Phenylamino isothiazole carboxamidines as MEK inhibitors](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

